Physician profile
Peter A Donnan
NPI 1477523371
$2,519.20
in general payments reported to CMS, 2019-2025
28 companies · $708 in 2025
The $708 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $164 · 2021: $89.08 · 2022: $180 · 2023: $535 · 2024: $549 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $444.81 | 2019-2025 | |
| Amgen INC. | $204.93 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $190.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $177.57 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $141.70 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.99 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $125.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Dexcom, INC. | $117.32 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $89.89 | 2023-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $83.02 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $80.55 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $71.76 | 2023-2025 | Voquezna |
| Astellas Pharma US INC | $70.99 | 2024-2025 | Veozah |
| Radius Health, INC. | $67.55 | 2024-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $61.92 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $61.39 | 2025 | Intellis Adaptivestim |
| Inari Medical, INC. | $55.00 | 2024-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbvie INC. | $54.08 | 2023 | Vraylar |
| Exact Sciences Corporation | $47.86 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $46.26 | 2019-2022 | |
| Esperion Therapeutics, INC. | $44.10 | 2020-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $30.50 | 2024 | |
| Dynavax Technologies Corporation | $25.94 | 2024 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $25.87 | 2019-2021 | |
| Edwards Lifesciences Corporation | $24.66 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| E.R. Squibb & Sons, L.L.C. | $19.16 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.32 | 2023 | Onpattro |
| Paratek Pharmaceuticals, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Donnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.